The influence of fruit and vegetable consumption and genetic variation on NAD(P)H:quinone oxidoreductase (NQO1) phenotype in an endoscopy-based population

Nutrition and Cancer

Volumn 60, Issue 2, 2008, Pages 204-215

  Tijhuis, Mariken J ^a   Boerboom, Anne Marie J F ^a   Visker, Marleen H P W ^a   Camp, Liesbeth Op Den ^a   Nagengast, Fokko M ^b   Tan, Adriaan C I T L ^c   Rietjens, Ivonne M C M ^a   Kok, Frans J ^a   Aarts, Jac M M J G ^a   Kampman, Ellen ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFE2L2; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; ENZYME ACTIVITY; FEMALE; FRUIT; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN TISSUE; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHENOTYPE; POPULATION RESEARCH; RECTUM BIOPSY; SIGMOIDOSCOPY; VEGETABLE;

ADULT; AGED; COLORECTAL NEOPLASMS; ENZYME ACTIVATION; FEMALE; FRUIT; GENOTYPE; HUMANS; LIFE STYLE; LYMPHOCYTES; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; SIGMOIDOSCOPY; VARIATION (GENETICS); VEGETABLES;

EID: 41349107216     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580701684849     Document Type: Article

References (56)

1. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, et al.: NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 129, 77-97, 2000.
2. Monks TJ, Hanzlik RP, Cohen GM, and Ross D, Graham DG: Quinone chemistry and toxicity. Toxicol Appl Pharmacol 112, 2-16, 1992.
3. Siegel D, and Ross D: Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med 29, 246-253, 2000.
4. Ross D, and Siegel D: NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol 382, 115-144, 2004.
5. Ross D: Quinone reductases multitasking in the metabolic world. Drug Metab Rev 36, 639-654, 2004.
6. Sreerama L, Hedge MW, and Sladek NE: Identification of a class 3 aldehyde dehydrogenase in human saliva and increased levels of this enzyme, glutathione S-transferases, and DT-diaphorase in the saliva of subjects who continually ingest large quantities of coffee or broccoli. Clin Cancer Res 1, 1153-1163, 1995.
7. Gordon GB, Prochaska HJ, and Yang LY: Induction of NAD(P)H:quinone reductase in human peripheral blood lymphocytes. Carcinogenesis 12, 2393-2396, 1991.
8. O'Dwyer PJ, Szarka CE, Yao KS, Halbherr TC, Pfeiffer GR, et al.: Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. J Clin Invest 98, 1210-1217, 1996.
9. Jaiswal AK: Human NAD(P)H:quinone oxidoreductase (NQO1) gene structure and induction by dioxin. Biochemistry 30, 10647-10653, 1991.
10. Park EJ, and Pezzuto JM: Botanicals in cancer chemoprevention. Cancer Metastasis Rev 21, 231-255, 2002.
11. Kwak MK, Wakabayashi N, and Kensler TW: Chemoprevention through the Keap1-Nrf2 signaling pathway by phase 2 enzyme inducers. Mutat Res 555, 133-148, 2004.
12. Platz EA, Willett WC, Colditz GA, Rimm EB, Spiegelman D, et al.: Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men. Cancer Causes Control 11, 579-588, 2000.
13. Nebert DW, Roe AL, Vandale SE, Bingham E, and Oakley GG: NAD(P)H: quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: A HuGE review. Genet Med 4, 62-70, 2002.
14. Gaedigk A, Tyndale RF, Jurima-Romet M, Sellers EM, Grant DM, et al.: NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics 8, 305-313, 1998.
15. Siegel D, McGuinness SM, Winski SL, and Ross D: Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 9, 113-121, 1999.
16. Traver RD, Horikoshi T, Danenberg KD, Stadlbauer TH, Danenberg PV, et al.: NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 52, 797-802, 1992.
17. Misra V, Grondin A, Klamut HJ, and Rauth AM: Assessment of the relationship between genotypic status of a DT-diaphorase point mutation and enzymatic activity. Br J Cancer 83, 998-1002, 2000.
18. Sarbia M, Bitzer M, Siegel D, Ross D, Schulz WA, et al.: Association between NAD(P)H: quinone oxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract. Int J Cancer 107, 381-386, 2003.
19. Basu S, Brown JE, Flannigan GM, Gill JH, Loadman PM, et al.: NAD(P)H:Quinone oxidoreductase-1 C609T polymorphism analysis in human superficial bladder cancers: relationship of genotype status to NQO1 phenotype and clinical response to Mitomycin C. Int J Oncol 25, 921-927, 2004.
20. Chao C, Zhang ZF, Berthiller J, Boffetta P, and Hashibe M: NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15, 979-987, 2006.
21. Hou L, Chatterjee N, Huang WY, Baccarelli A, Yadavalli S, et al.: CYP1A1 Val462 and NQO1 Ser187 polymorphisms, cigarette use, and risk for colorectal adenoma. Carcinogenesis 26, 1122-1128, 2005.
22. Jaiswal AK: Regulation of genes encoding NAD(P)H:quinone oxidoreductases. Free Radic Biol Med 29, 254-262, 2000.
23. Nioi P, and Hayes JD: Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. Mutat Res 555, 149-171, 2004.
24. Tijhuis MJ, Visker MH, Aarts JM, Peters WH, Roelofs HM, et al.: Glutathione S-transferase phenotypes in relation to genetic variation and fruit and vegetable consumption in an endoscopy-based population. Carcinogenesis 28, 848-857, 2007.
25. Donders-Engelen M, van der Heijden LJM, and Hulshof KFAM. Measures, weights, and Code Numbers 2003. Zeist, Wageningen: TNO-Nutrition and Food Research and Wageningen University (In Dutch); 2003.
26. NEVO. Nederlands Voedingsstoffenbestand [Dutch Food Composition Tables]. The Hague: Voedingscentrum; 2001.
27. Scholte B. VBS Food Calculation System. 4. BaS Nutrition Software; 2004.
28. den Dunnen JT, and Antonarakis SE: Nomenclature for the description of human sequence variations. Hum Genet 109, 121-124, 2001.
29. Yamamoto T, Yoh K, Kobayashi A, Ishii Y, Kure S, et al.: Identification of polymorphisms in the promoter region of the human NRF2 gene. Biochem Biophys Res Commun 321, 72-79, 2004.
30. Sambrook J, Fritsch EF, and Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1989.
31. Benson AM, Hunkeler MJ, and Talalay P: Increase of NAD(P)H:quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. Proc Natl Acad Sci U S A 77, 5216-5220, 1980.
32. De Haan LH, Boerboom AM, Rietjens IM, van Capelle D, De Ruijter AJ, et al.: A physiological threshold for protection against menadione toxicity by human NAD(P)H:quinone oxidoreductase (NQO1) in Chinese hamster ovary (CHO) cells. Biochem Pharmacol JID-0101032 64, 1597-1603, 2002.
33. O'Neill ME, Carroll Y, Corridan B, Olmedilla B, Granado F, et al.: A European carotenoid database to assess carotenoid intakes and its use in a five-country comparative study. Br J Nutr 85, 499-507, 2001.
34. Xia C, Taylor JB, Spencer SR, and Ketterer B: The human glutathione S-transferase P1-1 gene: modulation of expression by retinoic acid and insulin. Biochem J 292 ( Pt 3), 845-850, 1993.
35. Yao KS, Hageboutros A, Ford P, and O'Dwyer PJ: Involvement of activator protein-1 and nuclear factor-kappaB transcription factors in the control of the DT-diaphorase expression induced by mitomycin C treatment. Mol Pharmacol 51, 422-430, 1997.
36. Ng D, Kokot N, Hiura T, Faris M, Saxon A, et al.: Macrophage activation by polycyclic aromatic hydrocarbons: evidence for the involvement of stress-activated protein kinases, activator protein-1, and antioxidant response elements. J Immunol 161, 942-951, 1998.
37. Pool-Zobel B, and Veeriah S, Bohmer FD: Modulation of xenobiotic metabolising enzymes by anticarcinogens - focus on glutathione S-transferases and their role as targets of dietary chemoprevention in colorectal carcinogenesis. Mutat Res 591, 74-92, 2005.
38. Lampe JW, Chen C, Li S, Prunty J, Grate MT, et al.: Modulation of human glutathione S-transferases by botanically defined vegetable diets. Cancer Epidemiol Biomarkers Prev 9, 787-793, 2000.
39. Bonnesen C, Eggleston IM, and Hayes JD: Dietary indoles and isothiocyanates that are generated from cruciferous vegetables can both stimulate apoptosis and confer protection against DNA damage in human colon cell lines. Cancer Res 61, 6120-6130, 2001.
40. Chen C, Pung D, Leong V, Hebbar V, Shen G, et al.: Induction of detoxifying enzymes by garlic organosulfur compounds through transcription factor Nrf2: effect of chemical structure and stress signals. Free Radic Biol Med 37, 1578-1590, 2004.
41. Lewin B: Genes VI. 165, 1997.
42. Anonymous. Zo eet Nederland, 1998. Resultaten van de Voedselconsumptiepeiling 1997-1998. The Hague: Netherlands Nutrition Center; 1998.
43. Bogaards JJ, Verhagen H, Willems MI, van Poppel G, and Van Bladeren PJ: Consumption of Brussels sprouts results in elevated alpha-class glutathione S-transferase levels in human blood plasma. Carcinogenesis 15, 1073-1075, 1994.
44. Nijhoff WA, Grubben MJAL, Nagengast FM, Jansen JB, Verhagen H, et al.: Effects of consumption of Brussels sprouts on intestinal and lymphocytic glutathione S-transferases in humans. Carcinogenesis 16, 2125-2128, 1995.
45. Harth V, Donat S, Ko Y, Abel J, Vetter H, et al.: NAD(P)H quinone oxidoreductase 1 codon 609 polymorphism and its association to colorectal cancer. Arch Toxicol 73, 528-531, 2000.
46. van der Logt EM, Bergevoet SM, Roelofs HM, Te Morsche RH, Dijk Y, et al.: Role of epoxide hydrolase, NAD(P)H:quinone oxidoreductase, cytochrome P450 2E1 or alcohol dehydrogenase genotypes in susceptibility to colorectal cancer. Mutat Res 593, 39-49, 2006.
47. www.ncbi.nlm.nih.gov/SNP: accessed Jan 17th 2007, rs689457: NQO1 - 718 relative to transcription initiation site of GenBank Accession number M81596.
48. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, et al.: Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol Pharmacol 59, 263-268, 2001.
49. Kolesar JM, Pritchard SC, Kerr KM, Kim K, Nicolson MC, et al.: Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. Int J Oncol 21, 1119-1124, 2002.
50. Begleiter A, Leith MK, Doherty GP, Digbya TJ, and Pan S: Factors influencing the induction of DT-diaphorase activity by 1,2-dithiole-3-thione in human tumor cell lines. Biochem Pharmacol 61, 955-964, 2001.
51. Begleiter A, and Lange L: Lack of NQO1 induction in human tumor cells is not due to changes in the promoter region of the gene. Int J Oncol 20, 835-638, 2002.
52. Pan SS, Han Y, Farabaugh P, and Xia H: Implication of alternative splicing for expression of a variant NAD(P)H:quinone oxidoreductase-1 with a single nucleotide polymorphism at 465C∠T. Pharmacogenetics 12, 479-488, 2002.
53. Gasdaska PY, Fisher H, and Powis G: An alternatively spliced form of NQO1 (DT-diaphorase) messenger RNA lacking the putative quinone substrate binding site is present in human normal and tumor tissues. Cancer Res 55, 2542-2547, 1995.
54. Yao KS, Godwin AK, Johnson C, and O'Dwyer PJ: Alternative splicing and differential expression of DT-diaphorase transcripts in human colon tumors and in peripheral mononuclear cells in response to mitomycin C treatment. Cancer Res 56, 1731-1736, 1996.
55. Szarka CE, Yao KS, Pfeiffer GR, Balshem AM, Litwin S, et al.: Chronic dosing of oltipraz in people at increased risk for colorectal cancer. Cancer Detect Prev 25, 352-361, 2001.
56. Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, et al.: Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 21, 689-700, 2006.